

From: [Jarvis, Candace](#)
To: [James L'Italien, PhD \(jlitalien@avexis.com\)](#)
Cc: [Nancy Boman](#); [Jarvis, Candace](#); [Xu, Lei \(CBER\)](#); [Singer, Mike](#); [Byrnes, Andrew](#)
Subject: BLA 125694/0 | AveXis, Inc| Information Request 14 (Please Respond by November 20, 2018)
Date: Thursday, November 15, 2018 5:21:38 PM
Attachments: [image013.png](#) **Importance:** High

Good evening Dr. L'Italien,

We have the following request for information regarding BLA 125694.

Please direct us to the following documents in the BLA submission. If these documents have not been provided, please do so by November 20, 2018.

- a. Financial disclosure forms FDA 3454 and/or 3455
- b. Coding dictionary used for mapping investigator verbatim terms to preferred terms
- c. Case report forms Please confirm receipt.

Regards,

Candace N. Jarvis
Regulatory Project Manager
Center for Biologics Evaluation and Research
Office of Tissues and Advanced Therapies
U.S. Food and Drug Administration
Tel: 240-402-8315
candace.jarvis@fda.hhs.gov



THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone.